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Abstract Serotonin is a monoamine acting as a neurome-
diator in the central and peripheral nervous system.
Recently, serotonin has also been shown to inXuence T- and
B-cell function. The serotonin transporter is central in the
regulation of the serotonergic system and widely expressed
on cells of the immune system. A functional length poly-
morphism in the promoter of the serotonin transporter gene
(5-HTTLPR) has been implicated in the genetic back-
ground of depression. Psoriasis is a complex disease with a
polygenetic inheritance. In light of the role of T-cell medi-
ated inXammation in psoriasis and the increased prevalence
of depression in psoriatic patients, we analyzed the 5-
HTTLPR polymorphism in 309 patients with psoriasis vul-
garis and 315 healthy control individuals. No signiWcant
diVerences in genotype distribution and allele frequencies
were found. There was also no diVerence in the score of the
Hamilton Rating Scale for Depression in patients with pso-
riasis (n = 137) characterized by carriage of diVerent 5-
HTTLPR genotypes. These Wndings argue against a major
contribution of the 5-HTTLPR polymorphism to psoriasis
susceptibility and the occurrence of depressive symptoms
among psoriatic patients.
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Introduction
Psoriasis vulgaris is a complex disease with multifactorial
inheritance aVecting approximately 2–3% of the popula-
tion. It is believed that cells of the innate and acquired
immune system, among them dendritic cells and T-cells,
collaborate to produce a pattern of cutaneous angiogenesis,
inXammation and epidermal changes that underlie the for-
mation of sharply demarcated erythematosquamous
plaques, the typical clinical presentation of psoriasis [3].
Because psoriasis is a chronic, often widespread and stig-
matizing condition that may extensively reduce the quality
of life of aVected patients, the observed increased preva-
lence of depressive symptoms among patients compared
with healthy individuals [1] can possibly be regarded as
secondary to the manifestation of a signiWcant medical con-
dition. It is also not excluded that the psoriatic inXamma-
tory process plays a direct role via the constantly increased
production of mediators that may also inXuence mental
functions or that psoriasis and depression share common
risk factors at the genetic level. On the other hand, it has
been suggested that stress can aggravate skin inXammation
in patients with psoriasis, indicating another level of possi-
ble interactions between psychological symptoms and skin
inXammation.
The serotonergic system is a promising candidate for
establishing a neuroimmunological link between psoriatic
skin disease and psychological symptoms. In the central
R. Mössner (&) · D. Schmidt · A. Platzer · U. Krüger
Department of Dermatology, Georg-August-University, 
Von-Siebold-Strasse 3, 37075 Göttingen, Germany
e-mail: rmoessn@gwdg.de
G. Stiens
Gerontopsychiatrisches Zentrum, Rheinische Kliniken Bonn, 
Kaiser-Karl-Ring 20, 53111 Bonn, Germany
I. R. König
Institute of Medical Biometry and Statistics, 
University of Lübeck, Ratzeburger Allee 160, 
23538 Lübeck, Germany
K. Reich
Dermatologikum, Hamburg, Stephansplatz 5, 
20354 Hamburg, Germany444 Arch Dermatol Res (2009) 301:443–447
123
nervous system, serotonergic neurons project to almost all
regions of the brain and inXuence many physiological func-
tions such as pain, sleep, motor functions, neuroendocrine
circuits and the mood. The main producers of 5-HT are
enterochromaYn cells of the gut and the serotonergic neu-
rons of the brain, but 5-HT is stored in many cell types out-
side the central nervous system including platelets,
lymphocytes, monocytes/macrophages and dendritic cells
[6]. Recently, it has been shown that lymphocytes also syn-
thesize and excrete 5-HT [17]. The production of 5-HT is
increased at sites of inXammation and several functional
activities of 5-HT have been revealed that play an impor-
tant role in chronic inXammatory diseases such as psoriasis
including the activation of mast cell migration and adhesion
[9], the stimulation of cytokine release from dendritic cells
[8] and the mediation of dendritic cell–T-cell interactions
[17].
The expression and function of the serotonin transporter
(5-HTT), which is responsible for the uptake of 5-HT into
cells thereby removing 5-HT from the extracellular space,
is a key parameter in the regulation of 5-HT-mediated
eVects in the central nervous system and the immune sys-
tem [15]. The expression of 5-HTT is controlled by a repeat
length polymorphism in the 5-HTT linked polymorphic
region (5-HTTLPR). The long (high activity) allele of this
polymorphism is associated with a higher number of 5-
HTT molecules on lymphocytes [10]. The biological rele-
vance of the 5-HTTLPR polymorphism is underscored by
the recent Wnding of an association with primary pulmonary
hypertension [5], and the observed inXuence on the devel-
opment of depressive symptoms in individuals aZicted by
a negative life event as well as on suicidal behavior [11].
In this study, we used a case–control design to obtain
Wrst evidence whether the 5-HTTLPR polymorphism is
associated with psoriasis. We also compared depressive
symptoms in psoriatic patients characterized by carriage of
diVerent 5-HTTLPR genotypes.
Subjects and methods
Study participants
Unrelated German Caucasian patients with an established
diagnosis of chronic plaque-type psoriasis were enrolled
from the Department of Dermatology, University Hospital
Göttingen (309 individuals, 127 female, 182 male, age
46.0 § 14.3 years (mean § SD), positive family history in
140 cases). The control group consisted of healthy unre-
lated German Caucasians without a personal or family his-
tory of psoriasis (315 individuals, 146 female, 169 male,
age 35.6 § 12.1 years (mean § SD)) recruited from the
blood donor registry of the Department of Transfusion
Medicine, University Hospital Göttingen and from local
health-care personnel as described previously [20].
To assess the presence of depressive symptoms, the
Hamilton Rating Scale for Depression (HAM-D) was per-
formed in the subgroup of 137 patients of patients aged
between 18 and 60 years who were recruited between May
2004 and November 2005. The HAM-D is a validated scale
that is routinely used for the assessment of depression and
rates the severity of 21 symptoms typical of depression,
from which a sum score is calculated. The HAM-D can
take on values between 0 and 67, and the score of >8, >14
and >19 is considered to reXect a mild, moderate and severe
depression, respectively.
The study was approved by the Institutional Review
Board of the Medical Faculty of the University of Göttin-
gen, and informed consent was obtained from all partici-
pants.
Genotyping of the 5-HTT promoter polymorphism 
(5-HTTLPR)
Genomic DNA was prepared from peripheral blood mono-
nuclear cells according to the published protocols [13].
The 5-HTT linked polymorphic region (5-HTTLPR) of
the gene encoding SERT (SCL6A4) located on chromo-
some 17q11.1–12 was ampliWed by the Xanking oligonu-
cleotide primers 5-GAG GGA CTG AGC TGG ACA AC-3
and 5-GCA GCA GAC AAC TGT GTT CAT C-3. The
short (s) allele is 44 bp shorter than the long (l) allele due to
a 44 bp deletion [7]. PCR was performed in a Wnal solution
of 20 l containing between 200 and 600 ng genomic DNA,
0.2 mM dNTP, 0.2 mM deaza-GTP, 0.5 M of each primer,
2% dimethylsulfoxide, 2.5 U Taq polymerase in PCR buVer
(Promega).
After an initial denaturation for 3 min at 95°C, 43 cycles
of denaturing at 95°C for 30 s, annealing for 30 s and
extension at 72°C for 1 min were performed, followed by a
Wnal extension at 72°C for 10 min. Annealing was per-
formed at 65°C for the Wrst four cycles, 64°C for the subse-
quent four cycles and 63°C during the Wnal 35 cycles.
PCR products were visualized on an agarose gel contain-
ing ethidium bromide. The variants were detected accord-
ing to their size relative to a 100 bp DNA ladder (Fig. 1).
Statistical analysis
To determine whether the genotype frequencies conWrmed
with Hardy–Weinberg equilibrium, the equivalence test
proposed by Wellek was used (5% test level) with  =0 . 1
[24]. Odds ratios (ORs) and exact 95% conWdence intervals
(CIs) were calculated to compare the genotype frequencies.
DiVerences in genotype frequencies were investigated
using an exact Cochrane–Armitage trend test. DiVerencesArch Dermatol Res (2009) 301:443–447 445
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in the HAM-D among diVerent genotypes were compared
using the non-parametric Mann–Whitney U test. The over-
all signiWcance level was set to p = 0.05.
Results
The absolute and relative genotype frequencies of the 5-
HTTLPR polymorphism are given in Table 1. The geno-
type frequencies in cases and controls were in Hardy–
Weinberg equilibrium. The genotype frequencies were sim-
ilar among patients with psoriasis vulgaris and healthy con-
trols. In addition, there was no diVerence in genotype
frequencies between patients with early onset- (type I; age
at onset <40 years) and late onset psoriasis (type II; age at
onset ¸40 years).
HAM-D was 5.1 § 5.3 in psoriasis patients
(mean § SD), with 20% of patients suVering from an at
least mild depression (HAM-D >8). HAM-D was signiW-
cantly higher in female psoriasis patients compared with
male patients (7.2 § 5.9 vs. 3.7 § 4.5, p = 0.0001).
To assess whether allelic variants of 5-HTTLPR poly-
morphism may be associated with depressive symptoms in
psoriatic patients, the HAM-D was compared between
patients with psoriasis (n = 137) characterized by carriage
of 0, 1 or 2 s alleles, corresponding to the ll, ls and ss geno-
types, respectively. Mean and SD as well as median and 25
and 75% percentiles of the HAM-D were similar in these
subgroups (Table 2). As there was a signiWcant diVerence
in the HAM-D between male and female patients, HAM-D
values were also compared separately in male and female
carriers of 5-HTTLPR genotypes. No signiWcant diVerences
were observed in these subgroups (data not shown).
Discussion
To the best of our knowledge, this is the Wrst study to inves-
tigate a possible relationship between a functionally rele-
vant polymorphism in the promoter of the gene encoding
the serotonin transporter and an inXammatory skin disorder.
The control group showed genotype frequencies of the
5-HTTLPR polymorphism similar to those reported in an
Fig. 1 Example for genotyping 
of 5-HTTLPR in 18 probands. 
+ Positive control (genotype ls), 
¡ negative control, lanes P1, P2, 
P6, P8, P13, P17 genotype ls, 
lane P9 genotype ss, remaining 
probands genotype ll
100
800
700
900
1031 
600
300
200
400
500
bp + - P1 P2 P3 P4 P5 P6  P7  P8  P10  P11  P12  P13  P16  P14 P15  P17  P9 P18 
627 bp 
‚l‘ allele 
583 bp 
‚s‘ allele 
Table 1 5-HTTLPR genotype 
distribution
Psoriasis patients Control group
n = 309 n = 315
Genotype n (%) n (%) OR pa
ll 104 (33.7) 108 (34.3)
ls 144 (46.6) 155 (49.2) 1.08 (0.86–1.36)
ss 61 (19.7) 52 (16.5) 1.17 (0.74–1.85) 0.496
Type 1 psoriasis b Type 2 psoriasis c
n = 224 n =8 5
Genotype n (%) n (%)
ll 78 (34.8) 26 (30.6)
ls 107 (47.8) 37 (43.5) 1.28 (0.89–1.84)
ss 39 (17.4) 22 (25.9) 1.63 (0.79–3.39) 0.184
a Two-sided exact p from 
Cochrane-Armitage trend-test
b Type 1 psoriasis: age 
at onset <40 years
c Type 2 psoriasis: age 
at onset ¸40 years
Table 2 HAM-D in psoriasis patients according to 5-HTTLPR geno-
type
HAM-D 5-HTTLPR genotype
ll (n =4 8 ) l s  ( n = 67) ss (n =2 2 )
Mean (SD) 5.4 (5.7) 5.3 (5.3) 4.7 (5.4)
Median (range) 4 (0;25) 4 (0;21) 4 (0;26)
25. percentile 1 1 2
75. percentile 8 7.5 7446 Arch Dermatol Res (2009) 301:443–447
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earlier study with healthy German individuals [12]. We
found no association of the 5-HTTLPR polymorphism with
psoriasis vulgaris, and the obtained 95% CIs indicate that
major eVects are unlikely.
Depressive symptoms have been reported to be more
prevalent among psoriatic patients than among healthy
individuals [1]. However, it has not been established
whether depression is exclusively a consequence of the
impaired quality of life and stigmatization of the disease or
whether neuroimmunological mechanisms may also con-
tribute to depressive symptoms. The observation of ele-
vated levels of proinXammatory cytokines in depressive
patients and the relatively frequent induction of depressive
symptoms during the therapeutic application of interferon-
point to a possible role of proinXammatory cytokines in the
development of depressive disorders [19]. The reduction of
depressive symptoms in patients with psoriasis treated with
the TNF-antagonist etanercept parallel to the improvement
of skin symptoms [23] could, therefore, be interpreted not
only as an indirect eVect, but also as a direct eVect related
to the modulation of peripheral or central neurological
functions.
Both depression and psoriasis are complex diseases.
Carriage of the ‘s’ allele of the 5-HTTLPR polymorphism
has been shown to inXuence susceptibility to develop
depressive symptoms after stressful life events but also in
association with other diseases such as Parkinson’s disease
[4, 14, 25]. In our study, we could not Wnd a signiWcant
diVerence in the HAM-D among carriers of diVerent 5-
HTTLPR genotypes. However, there are signiWcant limita-
tions to this Wnding. Low overall HAM-D values among
patients with psoriasis in our patient sample may indicate
an under-representation of patients with more pronounced
depressive symptoms. This is possibly related to the fact
that the majority of patients was recruited from a special-
ized outpatient clinic with optimized patient care. From
previous studies, it is evident that diVerent factors are likely
to confound the presence and severity of depressive symp-
toms in psoriasis including gender, severity of skin symp-
toms and impairment of quality of life [21]. In accordance
with the earlier results [18], more pronounced depressive
symptoms were observed among female compared with
male patients in this study, possibly as a result of gender-
speciWc diVerences in the prevalence of depression and in
the impact of skin diseases on overall well being and self-
perception. In light of these Wndings, it is likely that much
larger studies are necessary to establish a relationship
between depressive symptoms and genetic variations such
as the 5-HTTLPR polymorphism in psoriasis, and that the
results obtained with a subgroup of psoriatic patients in this
study can only be regarded as preliminary.
The serotonin/serotonin transporter system is a possible
link between neuropsychological and immunological func-
tions that may particularly be relevant in diseases such as
psoriasis that are characterized by stress-induced chronic
inXammation and an increased prevalence of depression. In
this pilot study, we failed to demonstrate an association
between psoriasis and the functionally relevant 5-HTTLPR
polymorphisms of the serotonin transporter. There was also
no association between depressive symptoms as measured
by the HAM-D and carriage of diVerent 5-HTTLRP geno-
types in a subgroup of patients with psoriasis. This does not
exclude a small contribution of the 5-HTTLPR polymor-
phism to psoriasis susceptibility or a modulatory eVect on
the development of depressive symptoms in patients
aVected by the disease. The speciWc limitation of the study
related to the small number of individuals enrolled is under-
lined by recent studies indicating that analysis of several
thousand individuals may be necessary to detect associa-
tions between SNPs of genes involved in psoriasis patho-
physiology and the disease [16]. However, smaller studies
with hundreds of patients have, for example, been able to
identify association between the 5-HTTLPR polymorphism
and anxiety-related personality traits in line with the con-
clusion that the Wndings from the present investigation at
least argue against a major role of the 5-HTTLPR polymor-
phism in psoriasis [22]. In addition, it may be necessary to
analyse genetic inXuences on depression separately in male
and female patients with psoriasis, as depressive symptoms
tend to be more severe in woman—as in our study—and
genetic eVects of the 5-HTTLPR may be superimposed by
gender eVects. Finally, other functionally relevant genetic
variations of the serotonergic system have been identiWed
including a variable number of tandem repeat polymor-
phism in intron 2 of the 5-HTT gene and polymorphism of
serotonin receptors that could play a role in the pathogene-
sis of psoriasis and depressive symptoms in psoriasis
patients [2]. Larger prospective trials are needed to evaluate
the genetic basis of the complex interaction of psoriasis,
environmental stressors, gender and development of
depressive symptoms.
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